Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00207077 · ClinicalTrials.gov registry record · Phase 1

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

A Phase 1 study of Neoplasms, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
33
Enrollment target
1
Study location

NCT00207077 is a Phase 1 study of Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 33 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00207077, a Phase 1 study of Neoplasms, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Conditions Studied

Neoplasms

Interventions

  • DRUG Cetuximab + Erlotinib

Study Locations (1)

Delaware

  • Christiana Care Health Services, Inc. - Newark

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2005-08
Est. Completion 2007-05
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00207077

The ClinicalTrials.gov registry entry for NCT00207077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Cetuximab + Erlotinib is the first listed.

NCT00207077 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.

Frequently Asked Questions

What is clinical trial NCT00207077 about?

NCT00207077 is a clinical study titled "Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors". The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

What is the current status of trial NCT00207077?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-08. Estimated completion is 2007-05.

What conditions does trial NCT00207077 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00207077?

The interventions under investigation include: Cetuximab + Erlotinib (DRUG).

Who is sponsoring clinical trial NCT00207077?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00207077 being conducted?

This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Delaware

All trials with a study site in Delaware

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.